Unknown

Dataset Information

0

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.


ABSTRACT: PURPOSE:Ibrutinib has shown activity in non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in untreated non-germinal center B-cell DLBCL. PATIENTS AND METHODS:Patients were randomly assigned at a one-to-one ratio to ibrutinib (560 mg per day orally) plus R-CHOP or placebo plus R-CHOP. The primary end point was event-free survival (EFS) in the intent-to-treat (ITT) population and the activated B-cell (ABC) DLBCL subgroup. Secondary end points included progression-free survival (PFS), overall survival (OS), and safety. RESULTS:A total of 838 patients were randomly assigned to ibrutinib plus R-CHOP (n = 419) or placebo plus R-CHOP (n = 419). Median age was 62.0 years; 75.9% of evaluable patients had ABC subtype disease, and baseline characteristics were balanced. Ibrutinib plus R-CHOP did not improve EFS in the ITT (hazard ratio [HR], 0.934) or ABC (HR, 0.949) population. A preplanned analysis showed a significant interaction between treatment and age. In patients age younger than 60 years, ibrutinib plus R-CHOP improved EFS (HR, 0.579), PFS (HR, 0.556), and OS (HR, 0.330) and slightly increased serious adverse events (35.7% v 28.6%), but the proportion of patients receiving at least six cycles of R-CHOP was similar between treatment arms (92.9% v 93.0%). In patients age 60 years or older, ibrutinib plus R-CHOP worsened EFS, PFS, and OS, increased serious adverse events (63.4% v 38.2%), and decreased the proportion of patients receiving at least six cycles of R-CHOP (73.7% v 88.8%). CONCLUSION:The study did not meet its primary end point in the ITT or ABC population. However, in patients age younger than 60 years, ibrutinib plus R-CHOP improved EFS, PFS, and OS with manageable safety. In patients age 60 years or older, ibrutinib plus R-CHOP was associated with increased toxicity, leading to compromised R-CHOP administration and worse outcomes. Further investigation is warranted.

SUBMITTER: Younes A 

PROVIDER: S-EPMC6553835 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

Younes Anas A   Sehn Laurie H LH   Johnson Peter P   Zinzani Pier Luigi PL   Hong Xiaonan X   Zhu Jun J   Patti Caterina C   Belada David D   Samoilova Olga O   Suh Cheolwon C   Leppä Sirpa S   Rai Shinya S   Turgut Mehmet M   Jurczak Wojciech W   Cheung Matthew C MC   Gurion Ronit R   Yeh Su-Peng SP   Lopez-Hernandez Andres A   Dührsen Ulrich U   Thieblemont Catherine C   Chiattone Carlos Sergio CS   Balasubramanian Sriram S   Carey Jodi J   Liu Grace G   Shreeve S Martin SM   Sun Steven S   Zhuang Sen Hong SH   Vermeulen Jessica J   Staudt Louis M LM   Wilson Wyndham W  

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20190322 15


<h4>Purpose</h4>Ibrutinib has shown activity in non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in untreated non-germinal center B-cell DLBCL.<h4>Patients and methods</h4>Patients were randomly assigned at a one-to-one ratio to ibrutinib (560 mg per day orally) plus R-CHOP or placebo plus R-CHOP. The primary end point was event-free surviv  ...[more]

Similar Datasets

| S-EPMC4833756 | biostudies-literature
| S-EPMC7970687 | biostudies-literature
| S-EPMC3204728 | biostudies-literature
| S-EPMC5664395 | biostudies-literature
| S-EPMC8335825 | biostudies-literature
| S-EPMC3418716 | biostudies-literature
| S-EPMC3815174 | biostudies-literature
| S-EPMC3530691 | biostudies-literature
| S-EPMC7237534 | biostudies-literature
| S-EPMC4616024 | biostudies-literature